Néovacs is a French biotechnology company that develops products and invests in innovative companies in Biotech and Medtech. It has distinct activities in Research and Development and investment.

Néovacs

Vaccibio Consulting | 712 followers on LinkedIn. 

Human Ressources & Accounting Manager at NEOVACS

Caroline Piot

Société de biotechnologies

Neovacs SA

Vaccibio Consulting

Apple Mobile Web Clips Icon

HSTS

Global Site Tag

US Privacy User Signal Mechanism

IPv6

Google Analytics 4

HSTS IncludeSubdomains PreLoad

IONOS

1and1

Jean-Jacques Bertrand

Miguel Sieler

Chief Executive Officer

Vincent Serra

Chief Scientific Officer

Daniel Zagury

Founder

Charlène Masson

Corporate Communication Director

Bio-Detection K9 is a biotech company that specializes in the canine detection of bacteria and viruses, particularly of covid-19.

Biotechnology Public Companies With Less Than $1B in Revenue

France Public Companies With More Than 10 Employees

Europe, Middle East, and Africa (EMEA) Public Companies

Europe, Middle East, and Africa (EMEA) Public Companies With Fewer Than 50 Employees

Neovacs, a spin-off from the Pierre & Marie Curie University in Paris, was founded on 1993 by Professor Daniel Zagury, one of France's most eminent immunologists and AIDS experts. Neovacs holds a broad patent portfolio and is developing several therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). At present, monoclonal antibodies are
widely used to neutralize cytokines and treat patients suffering from cytokine-related diseases. In contrast to exogenous therapies with monoclonal antibodies, Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.

Post-IPO Debt - Neovacs

Post-IPO Equity - Neovacs

Bpifrance

Novartis Venture Fund

Venture Round - Neovacs

Debiopharm Innovation Fund

Paris

Ile-de-France

France

Europe

Neovacs

Neovacs: collaboration agreement with CNRS

Neovacs: collaboration contract with INSERM team

Neovacs: new milestone for immunomodulators

Neovacs And FOCH Hospital Commit To Partnership On Research In Pneumology And Allergology

Pharnext Strengthens its Ties With Néovacs to Secure the Next Steps in its Development

Pharnext Announces a €2.5m Loan Agreement with Néovacs

A therapeutic vaccine targeting interferon alpha (IFNα) for the treatment of lupus, aiming to neutralize the cytokine and provide clinical benefits.

A therapeutic vaccine in development targeting cytokines IL-4 and IL-13 for the treatment of asthma and other allergies.

Neovacs invests in high-potential biotech and medtech companies, leveraging its scientific and financial expertise.

HTML5

Bootstrap

Apache Server

Google Analytics

Adobe Flash

F5 NGINX

Google Fonts

Adobe Fonts

Google Tag Manager

jQuery

Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.

Neovacs S.A.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 9, 2024 10:05 PM	b7ca5405
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 9, 2024 10:05 PM	d9feda6e
crunchbase trigger	general	Nov 27, 2024 12:50 PM	5ba11800
crunchbase profile	general	Nov 28, 2024 12:30 AM	53b3f0c8
li profile	general	Nov 9, 2024 10:05 PM	5012ad67
translate crunchbase fundingrounds	general	Nov 28, 2024 2:02 AM	a87c7649
peers	general	Nov 9, 2024 10:05 PM	f935f812
news basic	general	Nov 9, 2024 10:05 PM	a6fbf294
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NEOVACS

Néovacs

Last Close

0.00

25/11 08:00

Market Cap

50.16K

Beta: -

Volume Today

9.50M

Avg: -